Mifepristone: A Safe Method of Medical Abortion and Self-Managed Medical Abortion in the Post-Roe Era
- 19 August 2022
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Clinical Journal of Sport Medicine
- Vol. 29 (5), e534-e543
- https://doi.org/10.1097/mjt.0000000000001559
Abstract
Background: The U.S. Supreme Court's Dobbs v. Jackson Women's Health Organization decision on June 24, 2022 effectively overturned federal constitutional protections for abortion that have existed since 1973 and returned jurisdiction to the states. Several states implemented abortion bans, some of which banned abortion after 6 weeks and others that permit abortion under limited exceptions, such as if the health or the life of the woman is in danger. Other states introduced bills that define life as beginning at fertilization. As a result of these new and proposed laws, the future availability of mifepristone, one of two drugs used for medical abortion in the United States, has become the topic of intense debate and speculation. Areas of Uncertainty: Although its safety and effectiveness has been confirmed by many studies, the use of mifepristone has been politicized regularly since its approval. Areas of future study include mifepristone for induction termination and fetal demise in the third trimester and the management of leiomyoma. Data Sources: PubMed, Society of Family Planning, American College of Obstetrician and Gynecologists, the World Health Organization. Therapeutic Advances: The use of no-touch medical abortion, which entails providing a medical abortion via a telehealth platform without a screening ultrasound or bloodwork, expanded during the COVID-19 pandemic, and studies have confirmed its safety. With the Dobbs decision, legal abortion will be less accessible and, consequently, self-managed abortion with mifepristone and misoprostol will become more prevalent. Conclusions: Mifepristone and misoprostol are extremely safe medications with many applications. In the current changing political climate, physicians and pregnancy-capable individuals must have access to these medications.Keywords
This publication has 92 references indexed in Scilit:
- Abortion Law Around the World: Progress and PushbackAmerican Journal of Public Health, 2013
- Effect of mifepristone (25 mg) in treatment of uterine myoma in perimenopausal womanJournal of Mid-life Health, 2013
- Treatment for uterine fibroids: Searching for effective drug therapiesDrug Discovery Today: Therapeutic Strategies, 2012
- An unusual complication of unsafe abortionJournal of Family and Community Medicine, 2011
- Legal Barriers to Second-Trimester Abortion Provision and Public Health ConsequencesAmerican Journal of Public Health, 2009
- Mifepristone for the Treatment of Uterine LeiomyomasObstetrics & Gynecology, 2008
- Using telemedicine for termination of pregnancy with mifepristone and misoprostol in settings where there is no access to safe servicesBJOG: An International Journal of Obstetrics and Gynaecology, 2008
- Mifepristone (RU 486) in Cushing's syndromeActa Endocrinologica, 2007
- Estimation of pregnancy-related mortality risk by pregnancy outcome, United States, 1991 to 1999American Journal of Obstetrics and Gynecology, 2006
- Mifepristone and First Trimester AbortionClinical Obstetrics and Gynecology, 1996